Product Expansion Immunodiagnostic Systems (IDS) is actively developing and launching new immunoassay panels and automated analyzers, such as the IDS-iSYS platform and the i-Tracker assays, creating opportunities to cross-sell comprehensive diagnostic solutions to clinical laboratories seeking advanced testing capabilities.

Strategic Acquisitions The recent acquisition by PerkinElmer and integration into Euroimmun enhances IDS's market reach and product portfolio, enabling sales teams to position these expanded offerings to existing customers looking for integrated diagnostic solutions from a globally recognized brand.

COVID Testing Demand IDS's development and launch of SARS-CoV-2 IgM and IgG antibody tests during the pandemic highlights ongoing opportunities for sales in infectious disease diagnostics, especially with laboratories and healthcare providers ramping up COVID-related testing capabilities.

Key Market Focus With a strong presence in the UK and collaborations with diagnostic partners like Technogenetics, there are significant sales opportunities in both domestic and international markets for automated and specialized immunoassays tailored for clinical diagnostics.

Growth Through Innovation IDS’s focus on innovative immunoassay platforms and expanding assay panels positions it well to capitalize on evolving laboratory testing needs, offering a competitive edge to laboratories seeking high-throughput, automated solutions aligned with market trends.